Seattle, WA, Aug-12, 2018 — / Chronicle India News / —
Absence of alternative affordable therapies and patent losses are expected to foster growth of pain management drugs market over the forecast period
Lupin Pharmaceuticals launched generic pain medication of Allergan’s Norco (hydrocodone/acetaminophen) in 2017 in the U.S. Daiichi Sankyo Company, Limited announced launch of Narurapid (hydromorphone hydrochloride) tablets and Narusus tablets for cancer pain treatment in 2017. Digital therapeutic company 2Morrow, Inc. launched an app for pain management in February 2018. Avella launched pain and addiction management mobile app for physicians in 2017. These applications will help physicians in management of their patients along with curbing the opioid (drugs taken in pain management) addiction problems.
Eli Lilly and Company are trying to gain approval for a monoclonal antibody Tanezumab, a humanized monoclonal immunoglobulin G2 antibody, and the drug is in phase III clinical trials for the treatment of chronic low back pain and chronic pain from osteoarthritis.
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1697
Pain Management Drugs Market report 2016-2020 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The Pain Management Drugs market research report is a professional and in-depth study on the current state of Pain Management Drugs Industry.
Key Vendors of Pain Management Drugs Market: Some major players operating in the pain management drugs market include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories, Purdue Pharma L.P., GlaxoSmithKline Plc, Johnson & Johnson, and F. Hoffmann La Roche Ltd.
Pain Management Drugs market report analyses the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, and market demand and supply scenarios.
Regions of Pain Management Drugs market:
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1697
In the end, the report makes some important proposals for a new project of Pain Management Drugs Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2016-2020 global Pain Management Drugs industry covering all important parameters.
Pain Management Drugs driver
Pain Management Drugs challenge
Pain Management Drugs trend
The global pain management drugs market is expected to exhibit a CAGR of 9% over the forecast period (2018–2026), owing to increasing product launches by generic manufacturers such as Lupin and others
Among drug class, opioids segment is expected to dominate the pain management drugs market over the forecast period
Majority of the drugs in the pain management drugs market has lost patent protection due to which generic manufacturers have been able to enter into the market
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1697